ArticleTranslational cancer research2025
Development and validation of a preoperative nomogram for predicting residual tumor risk in breast cancer patients undergoing excisional biopsy.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current research on breast-conserving surgery (BCS) focuses on recurrence and survival but overlooks the issue of residual tumors post-excisional biopsy. These remnants, crucial for surgical planning, often necessitate additional excisions, impacting BCS success. Our 5-year study of excisional biopsy patients identifies risk factors for residual tumors, offering insights to improve surgical decisions. Methods: This study examined 233 breast cancer patients split into training and validation groups (2:1 ratio). Logistic regression models identified predictors of post-biopsy residual tumors status, leading to the creation and validation of a preoperative nomogram for residual risk. Results: In this study of 233 patients, 23.9% with BCS had residual tumors after biopsy, significantly less than those in the non-BCS group (P<0.001). Tumor size, biopsy method, and histopathological subtype were crucial in predicting residual tumors and were used to develop a nomogram, which showed strong predictive accuracy for preoperative residual tumor status. This tool enhances preoperative risk stratification and aids in the formulation of personalized surgical strategies by providing visual quantification of the probabilities associated with oncological clearance parameters. Conclusions: We developed a clinically practical nomogram for predicting residual tumor status following excisional biopsy, facilitating preoperative risk stratification and personalized surgical strategy. Further prospective studies are necessary to evaluate its generalizability and accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.